Strong antitumor activity of bevacizumab and aflibercept in Neuroendocrine Carcinomas: In-depth preclinical study.
<br>Background Neuroendocrine carcinoma (NEC) is a rare and very aggressive tumor. It has been greatly understudied and very little is known about optimal treatment strategy for patients with this disease. The purpose of this study was to evaluate in vivo whether anti-VEGF drugs could be a therapeutic alternative for these tumors with a poor prognosis. Methods We have developed two xenograft models using either human cell line derived from lung (H460) or from colon (COLO320) NEC to assess the effect of two antiangiogenic drugs, aflibercept and bevacizumab, on tumor growth and their pathological characteristics. Additionally, tumors were subjected to immunohistochemistry staining and proteins were measurement with western blot and ELISA. Results Both aflibercept and bevacizumab showed significant antitumor activity (p<0.001). In the H460 model, aflibercept resulted in 94% tumor growth inhibition (TGI) and bevacizumab treatment resulted in 72.2% TGI. Similarly, in the COLO320 model, aflibercept and bevacizumab resulted in 89.3% and 84% TGI, respectively. Moreover, antitumor activity occurs early after treatment initiation. Using Tumor Control Index score, which address the kinetics of tumor growth in a way comparable to the methods used in human clinical studies, we confirmed that both drugs inhibit significantly tumor growth. When tumor stabilization was evaluated, aflibercept shows higher ability to stabilize NEC tumors than bevacizumab. Conclusion Results derived from this study strongly support anti-VEGF therapies, especially aflibercept, as a novel therapeutic option in NECs. Further studies are necessary, but our observations encourage the evaluation of antiangiogenics in clinical trials combined with standard chemotherapy.<br>.